These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17485499)

  • 21. Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 mycobacterium tuberculosis clinical isolates.
    Mestdagh M; Realini L; Fonteyne PA; Rossau R; Jannes G; Mijs W; DE Smet KA; Portaels F; Van den Eeckhout E
    Microb Drug Resist; 2000; 6(4):283-7. PubMed ID: 11272256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and Biological Evaluation of N-Alkyl-3-(alkylamino)-pyrazine-2-carboxamides.
    Semelkova L; Konecna K; Paterova P; Kubicek V; Kunes J; Novakova L; Marek J; Naesens L; Pesko M; Kralova K; Dolezal M; Zitko J
    Molecules; 2015 May; 20(5):8687-711. PubMed ID: 26007174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Ragunathan P; Cole M; Latka C; Aragaw WW; Hegde P; Shin J; Subramanian Manimekalai MS; Rishikesan S; Aldrich CC; Dick T; Grüber G
    ACS Chem Biol; 2021 Jun; 16(6):1030-1039. PubMed ID: 33984234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological detection of pyrazine-2-carboxylic acid for the detection of pyrazinamide resistance in Mycobacterium tuberculosis.
    Florentini EA; Angulo N; Gilman RH; Alcántara R; Roncal E; Antiparra R; Toscano E; Vallejos K; Kirwan D; Zimic M; Sheen P
    PLoS One; 2020; 15(11):e0241600. PubMed ID: 33151985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron enhances the antituberculous activity of pyrazinamide.
    Somoskovi A; Wade MM; Sun Z; Zhang Y
    J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
    Rajendran V; Sethumadhavan R
    J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.
    Lee KW; Lee JM; Jung KS
    J Korean Med Sci; 2001 Oct; 16(5):537-43. PubMed ID: 11641519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
    Yamamoto S; Toida I; Watanabe N; Ura T
    Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD.
    Gopal P; Nartey W; Ragunathan P; Sarathy J; Kaya F; Yee M; Setzer C; Manimekalai MSS; Dartois V; Grüber G; Dick T
    ACS Infect Dis; 2017 Nov; 3(11):807-819. PubMed ID: 28991455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pyrazinamide monoresistant Mycobacterium tuberculosis in Manisa region, Turkey].
    Ozkütük N; Ecemiş T; Sürücüoğlu S
    Mikrobiyol Bul; 2008 Oct; 42(4):585-90. PubMed ID: 19149079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.
    Yüksel P; Tansel O
    New Microbiol; 2009 Apr; 32(2):153-8. PubMed ID: 19579692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
    Salfinger M; Kafader FM
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jul; 265(3-4):404-7. PubMed ID: 3118600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.
    Miyagi C; Yamane N; Yogesh B; Ano H; Takashima T
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):111-6. PubMed ID: 14972380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
    Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
    J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, antimycobacterial activity and in vitro cytotoxicity of 5-chloro-N-phenylpyrazine-2-carboxamides.
    Zitko J; Servusová B; Paterová P; Mandíková J; Kubíček V; Kučera R; Hrabcová V; Kuneš J; Soukup O; Doležal M
    Molecules; 2013 Dec; 18(12):14807-25. PubMed ID: 24317522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite?
    den Hertog AL; Sengstake S; Anthony RM
    Pathog Dis; 2015 Aug; 73(6):ftv037. PubMed ID: 25994506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is pyrazinamide bactericidal against Mycobacterium tuberculosis?
    Heifets LB; Lindholm-Levy PJ
    Am Rev Respir Dis; 1990 Jan; 141(1):250-2. PubMed ID: 2105072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.
    Kim HJ; Kwak HK; Lee J; Yun YJ; Lee JS; Lee MS; Min SY; Park SK; Kang HS; Maeng YH; Kim SY; Kim SY; Kook YH; Kim YR; Lee KH
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):98-103. PubMed ID: 22236853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis.
    Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
    Gene; 2016 Apr; 581(1):31-42. PubMed ID: 26784657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.